Trials / Completed
CompletedNCT05320757
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a window study where treatment-naïve patients will receive olaparib before definitive treatment. The aim is to evaluate the DNA damage and inflammatory response after PARP inhibitor.
Detailed description
Patients with high-risk endometrial cancers are prone to develop recurrence. The response rate to conventional chemotherapy in persistent or recurrent endometrial cancer is poor. Recent research demonstrated that immune checkpoint with or without targeted therapy was an effective treatment option. However, the change of immune landscape in the blood and tumor after PARPi is not clear.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib | a PARP inhibitor |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
- First posted
- 2022-04-11
- Last updated
- 2025-06-11
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT05320757. Inclusion in this directory is not an endorsement.